Sign in3 stories
San Diego based VivoSim said Nasdaq confirmed it meets the $2.5 million stockholders' equity rule, while new milestone cash and a warrant financing lifted its cash position to $10.1 million.
SEC filing
The filing shows Armistice Capital already holds 31.18% of VivoSim before the offering, with warrant terms tied to a stockholder-approval trigger.
SEC filing
The San Diego preclinical testing company will sell shares and warrants at $0.85 apiece to one healthcare-focused institutional investor, with closing expected July 17, 2026.
SEC filing